Literature DB >> 11906621

Sclerosed hemangioma and sclerosing cavernous hemangioma of the liver: a comparative clinicopathologic and immunohistochemical study with emphasis on the role of mast cells in their histogenesis.

Hala R Makhlouf1, Kamal G Ishak.   

Abstract

BACKGROUND/AIMS: Sclerosed hemangiomas of the liver are rare. To date, their histopathology, immunohistochemistry, and the role of mast cells (MC) in their histogenesis have not been systematically studied. PATIENTS/
METHODS: Clinical, histopathologic and immunohistochemical features of 20 sclerosed hemangiomas were compared with those of 18 sclerosing cavernous hemangiomas. The number of MC was quantified and compared in all cases, using a tryptase immunostain.
RESULTS: Compared to patients with sclerosed hemangiomas, those with sclerosing hemangiomas were younger (mean age, 63 versus 71 years); had larger tumors (mean 6 +/- 4.73 versus 3 +/- 2.2 cm); presented with a mass more frequently, and epigastric pain less frequently. Sclerosing hemangiomas, but not sclerosed hemangiomas, were more frequent in males than in females. Sclerosing hemangiomas occurred much more frequently in the right lobe than sclerosed hemangiomas. Sclerosing hemangiomas had less fibrosis, hyalinization, and elastic fibers than sclerosed hemangiomas (p = 0.00004). Numerous thick-walled blood vessels were a feature of sclerosed hemangiomas but not of sclerosing hemangiomas. Collagen IV, and laminin were more uniformly positive in sclerosing hemangiomas than in sclerosed hemangiomas. Increased immunoreactivity for smooth muscle actin was present in sclerosed hemangiomas more often than in sclerosing hemangiomas. FVIII-R Ag, CD34, and CD31 were more diffusely positive in sclerosing hemangiomas than in sclerosed hemangiomas. In sclerosing hemangiomas, the mean number of tryptase-positive MC per high power field (MC/HPF) varied from 8.25 +/- 6.23 in vascular areas to 1.6 +/- 4.01 in sclerotic areas. In comparison, the mean number of MC in sclerosed hemangiomas, was 4.3 +/- 5.01 in vascular areas, and 0.86 +/- 0.58 in sclerotic areas (p = 0.0095). The number of MC was significantly correlated with vascular proliferation and inversely related to the degree of fibrosis (p < 0.0001).
CONCLUSIONS: This study demonstrates certain distinct clinical and histopathologic differences between sclerosing cavernous hemangiomas and sclerosed hemangiomas of the liver. We have established the presence of MC in those tumors, and suggest possible involvement of the MC in angiogenesis, and the regression process and development of fibrosis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11906621     DOI: 10.1046/j.0106-9543.2001.01604.x

Source DB:  PubMed          Journal:  Liver        ISSN: 0106-9543


  21 in total

1.  Sclerosed hemangioma of the liver: possible diagnostic value of diffusion-weighted magnetic resonance imaging.

Authors:  Tomoyuki Hida; Akihiro Nishie; Tsuyoshi Tajima; Akinobu Taketomi; Shin-ichi Aishima; Hiroshi Honda
Journal:  Jpn J Radiol       Date:  2010-05-01       Impact factor: 2.374

2.  A sclerosing hemangioma of the liver.

Authors:  Ji Soo Song; Yo Na Kim; Woo Sung Moon
Journal:  Clin Mol Hepatol       Date:  2013-12

Review 3.  Angiogenesis and Hepatic Fibrosis: Western and Chinese Medicine Therapies on the Road.

Authors:  Jing-Si Wang; Qiu-Yun Zhang; Jin-Lian Cheng; Lan-Yu Chen; Nai-Li Yao; Gui-Zhi Sun; Yu-Ling Chu
Journal:  Chin J Integr Med       Date:  2018-06-25       Impact factor: 1.978

4.  Sclerosing hemangioma in the liver.

Authors:  Yong Moon Shin
Journal:  Korean J Hepatol       Date:  2011-09

5.  Sclerosed hemangioma of the liver.

Authors:  So Young Jin
Journal:  Korean J Hepatol       Date:  2010-12

6.  Utility of contrast-enhanced ultrasonography with perflubutane in evaluating indications for diagnostic percutaneous tumor biopsy in a case of hepatic sclerosed hemangioma.

Authors:  Yusuke Ando; Masatoshi Ishigami; Yoji Ishizu; Teiji Kuzuya; Takashi Honda; Yoshiki Hirooka
Journal:  Clin J Gastroenterol       Date:  2018-06-21

Review 7.  The complex functions of mast cells in chronic human liver diseases.

Authors:  Barbara Franceschini; Giorgia Ceva-Grimaldi; Carlo Russo; Nicola Dioguardi; Fabio Grizzi
Journal:  Dig Dis Sci       Date:  2006-11-11       Impact factor: 3.487

Review 8.  Hepatic Sclerosed Hemangioma: a case report and review of the literature.

Authors:  Shunsuke Miyamoto; Akihiko Oshita; Yutaka Daimaru; Masaru Sasaki; Hideki Ohdan; Atsushi Nakamitsu
Journal:  BMC Surg       Date:  2015-04-17       Impact factor: 2.102

9.  Sclerosed Hemangioma Accompanied by Multiple Cavernous Hemangiomas of the Liver.

Authors:  Michiko Yuki; Yuko Emoto; Yuichi Kinoshita; Katsuhiko Yoshizawa; Takashi Yuri; Airo Tsubura
Journal:  Am J Case Rep       Date:  2015-06-27

10.  Sclerosing haemangiomas of the liver: two cases of mistaken identity.

Authors:  C Lauder; G Garcea; H Kanhere; G J Maddern
Journal:  HPB Surg       Date:  2009-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.